Immune Tolerance, Restored.
Our Company
AbolerIS Pharma is a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from autoimmune diseases and organ transplantation rejection. We are developing potentially best-in-class and first-in-class, curative-intent therapies designed to restore immune tolerance by inducing an immune system reset.
Our Science
AbolerIS Pharma aims to develop potentially best-in-class and first-in-class, curative-intent therapies designed to restore immune tolerance by inducing an immune system reset.
Lead Program
At AbolerIS, we envision a future where patients suffering from autoimmune diseases can enjoy long-term remission and improved quality of life through therapies that are effective and safe. We are advancing a novel class of antibodies that target CD45RC, a key marker on pathogenic Effector T and B cells. Treatment with the antibody restores immune tolerance by selectively depleting the Effector cells, while preserving Regulatory cells and overall immune memory.
AbolerIS’ lead program in Phase 1, ABO21009, is designed to demonstrate broad efficacy in multiple autoimmune disorders with large unmet medical needs including rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and organ transplantation.
Latest updates
